Similar articles for PMID: 22021667

Year	Number of Results
1994	1
1995	1
1996	1
2001	1
2002	1
2003	4
2004	3
2005	4
2006	2
2007	4
2008	5
2009	8
2010	12
2011	12
2012	20
2013	14
2014	5
2015	5
2016	6
2017	5
2018	4
2019	6
2020	5
2021	8
2022	5
2024	0

1

Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.

Monsees GM, Malone KE, Tang MT, Newcomb PA, Li CI. Monsees GM, et al. J Natl Cancer Inst. 2011 Dec 7;103(23):1752-60. doi: 10.1093/jnci/djr399. Epub 2011 Oct 21. J Natl Cancer Inst. 2011. PMID: 22021667 Free PMC article.

2

Second primary breast cancer occurrence according to hormone receptor status.

Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Kurian AW, et al. J Natl Cancer Inst. 2009 Aug 5;101(15):1058-65. doi: 10.1093/jnci/djp181. Epub 2009 Jul 9. J Natl Cancer Inst. 2009. PMID: 19590058 Free PMC article.

3

Bisphosphonates: beyond prevention of bone metastases.

Rennert G. Rennert G. J Natl Cancer Inst. 2011 Dec 7;103(23):1728-9. doi: 10.1093/jnci/djr441. Epub 2011 Oct 21. J Natl Cancer Inst. 2011. PMID: 22021669 No abstract available.

4

Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients.

Korde LA, Doody DR, Hsu L, Porter PL, Malone KE. Korde LA, et al. Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):165-173. doi: 10.1158/1055-9965.EPI-17-0556. Epub 2017 Dec 18. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 29254937 Free PMC article.

5

Bisphosphonates and other bone agents for breast cancer.

O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. O'Carrigan B, et al. Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4. Cochrane Database Syst Rev. 2017. PMID: 29082518 Free PMC article. Review.

6

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M. Pavlakis N, et al. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. doi: 10.1002/14651858.CD003474.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034900 Updated. Review.

7

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S. Lash TL, et al. J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15. J Natl Cancer Inst. 2011. PMID: 21325141 Free PMC article.

8

Relationship between diabetes and risk of second primary contralateral breast cancer.

Li CI, Daling JR, Tang MT, Malone KE. Li CI, et al. Breast Cancer Res Treat. 2011 Jan;125(2):545-51. doi: 10.1007/s10549-010-1035-4. Epub 2010 Jul 13. Breast Cancer Res Treat. 2011. PMID: 20625814 Free PMC article.

9

Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.

Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N. Swain SM, et al. J Natl Cancer Inst. 2004 Apr 7;96(7):516-23. doi: 10.1093/jnci/djh097. J Natl Cancer Inst. 2004. PMID: 15069113

10

Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies.

Ou YJ, Chiu HF, Wong YH, Yang CC, Yang YH. Ou YJ, et al. Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1286-1295. doi: 10.1002/pds.4302. Epub 2017 Aug 31. Pharmacoepidemiol Drug Saf. 2017. PMID: 28857419 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

129 results

Results by year